Rome V Gastroduodenal Disorders: Gastroenterology | May 2026

The Rome V Gastroduodenal Disorders chapter introduces several important conceptual, diagnostic, and therapeutic refinements across functional dyspepsia (FD), nausea/vomiting disorders, belching disorders, inability to belch syndrome, and rumination syndrome. The most clinically important changes are the stronger emphasis on symptom-pattern phenotyping, pragmatic clinical diagnosis, and more mechanistically aligned treatment algorithms.

1. Gastroduodenal Disorders Are Now Structured Into 5 Major Rome V Categories

Rome V classifies gastroduodenal disorders into 5 major categories:

Functional dyspepsia (FD)

Nausea and vomiting disorders

Excessive belching disorders

Inability to belch syndrome (new category)

*Rumination syndrome

This structure is more clinically intuitive and improves practical differentiation of meal-related symptoms, vomiting syndromes, and behavioral esophagogastric syndromes.

2. Functional Dyspepsia (FD): Rome V Prioritizes Symptom Phenotype Over Umbrella Label

A major conceptual change in Rome V is that although functional dyspepsia (FD) remains the umbrella diagnosis, the committee explicitly recommends that clinicians preferentially classify patients using the symptom phenotype:

Postprandial Distress Syndrome (PDS)

Epigastric Pain Syndrome (EPS)

or PDS–EPS overlap

This is one of the most important practical refinements in Rome V because it shifts emphasis away from “FD” as a broad label and toward phenotype-driven diagnosis and treatment.

Why this matters clinically

This improves:

pathophysiologic alignment,

treatment selection,

and clinical trial stratification.

3. Postprandial Epigastric Pain Is No Longer Automatically EPS

One of the most important Rome V refinements in dyspepsia is the clarification that:

Postprandial epigastric pain in the presence of PDS symptoms should be classified as PDS, not EPS.

This resolves one of the major ambiguities in Rome IV, where meal-related epigastric pain often created diagnostic overlap and therapeutic confusion.

Clinical significance

This is a major advance because patients with:

postprandial fullness,

early satiety,

and meal-triggered epigastric pain

are now recognized as belonging to the PDS spectrum, which better aligns with impaired accommodation / delayed gastric emptying physiology and favors prokinetic-directed management.

4. Rome V Defines “Postprandial” More Precisely: Within 2 Hours of Meals

Rome V now explicitly defines postprandial symptoms as those that:

begin or worsen within 2 hours of meal intake

This is a major methodological improvement because it gives a more physiologically meaningful and reproducible definition of meal-related symptom generation.

Symptoms occurring later than 2 hours are considered less likely to reflect classical postprandial dyspeptic physiology and may represent other mechanisms.

5. PDS and EPS Thresholds Are Now More Pragmatic and Clinically Usable

Rome V refines symptom thresholds to better reflect real-world disease burden:

PDS

Requires ≥2 days/week of:

bothersome postprandial fullness and/or

bothersome early satiation.

EPS

Requires ≥1 day/week of:

bothersome epigastric pain and/or

bothersome epigastric burning.

These thresholds are more clinically usable and better aligned with symptom burden than prior stricter formulations.

6. Rome V Introduces a Provisional Subdivision of EPS

Rome V newly acknowledges that EPS without PDS is not uniform and introduces a provisional subclassification:

Postprandial EPS = pain/burning starts or worsens after meals in ≥50% of episodes

Meal-unrelated EPS = pain/burning starts or worsens after meals in <50% of episodes

This is an important conceptual advance because it recognizes probable biological heterogeneity within EPS and sets up future mechanistic stratification.

7. Upper Endoscopy Is No Longer Mandatory in Routine FD Diagnosis

One of the most clinically relevant Rome V shifts is its more pragmatic diagnostic approach:

In routine clinical practice, patients with typical dyspeptic symptoms and no alarm features can be managed without mandatory upper endoscopy.

Instead, Rome V recommends:

clinical assessment,

medication review,

H. pylori testing,

selective investigations,

and endoscopy only when alarm/risk features are present.

For research, however, normal upper endoscopy remains mandatory.

This is a major clinical modernization of Rome criteria.

8. Helicobacter pylori Testing Is Mandatory in Dyspepsia Evaluation

Rome V makes one recommendation especially explicit:

H. pylori status should be determined in every patient with dyspeptic symptoms.

This is one of the strongest operational recommendations in the chapter.

Further:

if eradication leads to sustained symptom remission,

the condition should be classified as H. pylori–associated dyspepsia, not FD.

This is a clinically important distinction and avoids overdiagnosing DGBI in biologically attributable disease.

9. FD Pathophysiology Is Reframed as a Duodenal–Neuroimmune Disorder

One of the most important scientific advances in Rome V is the much stronger mechanistic emphasis on duodenal pathobiology in FD.

Rome V moves beyond older motility-centric models and reframes FD as a disorder involving:

impaired gastric accommodation,

delayed gastric emptying,

visceral hypersensitivity,

duodenal barrier dysfunction,

mucosal eosinophilia / mast cell activation,

neuroimmune signaling,

microbiome alteration,

bile acid signaling,

food-triggered immune activation,

and altered central processing.

The pathophysiology diagram on page 4 (Figure 1) is especially important because it visually presents FD as a multifactorial gut–brain disorder centered on duodenal barrier dysfunction, immune activation, neuroimmune dysregulation, and altered brain–gut signaling, rather than simply a gastric motor disorder.

This is one of the biggest conceptual scientific upgrades in Rome V gastroduodenal disease.

10. Rome V Introduces Clear Stepwise Treatment Algorithms for PDS and EPS

A major practical strength of Rome V is the introduction of structured treatment algorithms:

Figure 3 (page 7): PDS treatment algorithm

Figure 4 (page 8): EPS treatment algorithm

These are among the most clinically useful additions in the chapter.

PDS algorithm

Progresses through:

diet/lifestyle

PPI / first-line prokinetic / herbal therapy

endoscopy if needed

neuromodulator / brain–gut behavioral therapy

gastric emptying testing in refractory disease

second-line prokinetics if delayed emptying present

EPS algorithm

Progresses through:

diet/lifestyle

PPI / herbal therapy

endoscopy if needed

neuromodulator (especially TCA) / brain–gut behavioral therapy

nutritional support / alternate diagnoses in refractory disease

This is one of the most practice-changing parts of Rome V.

11. Rome V More Clearly Aligns Therapy With Phenotype

Rome V makes treatment more phenotype-specific:

PDS → prokinetics, accommodation-targeted therapy, gastric emptying stratification

EPS → acid suppression + neuromodulation (especially TCA)

This is one of the most clinically meaningful therapeutic refinements in Rome V.

Examples:

Acotiamide is emphasized for PDS

5-HT1A agonists (e.g., tandospirone/buspirone) for early satiety

Mirtazapine for weight loss / early satiety

TCA especially for EPS and pain-predominant phenotypes

12. Inability to Belch Syndrome Is a New Rome V Diagnosis

One of the most notable additions in Rome V is the formal inclusion of Inability to Belch Syndrome (retrograde cricopharyngeal dysfunction) as a new diagnostic entity.

This is a major addition because Rome formally recognizes a previously underdiagnosed but clinically distinctive syndrome characterized by:

inability to belch,

chest/neck gurgling,

bloating,

flatulence,

chest/epigastric discomfort.

This is one of the most clinically novel additions in the chapter.

13. Cannabinoid Hyperemesis Syndrome (CHS) Criteria Are More Stringent

Rome V substantially strengthens CHS criteria by requiring:

prolonged cannabis exposure (≥1 year),

excessive use (≥4 days/week or ≥15 doses/week),

and symptom resolution after sustained abstinence (≥6 months or 3 typical cycles).

This is a major improvement over Rome IV and greatly improves diagnostic specificity.

Clinical Bottom Line

The Rome V Gastroduodenal Disorders chapter is one of the most clinically actionable Rome V updates. Its major advances are:

phenotype-first FD classification (PDS/EPS over generic FD),

reclassification of meal-related epigastric pain,

explicit 2-hour postprandial definition,

pragmatic non-endoscopic clinical diagnosis,

mandatory H. pylori testing,

stronger duodenal–neuroimmune FD model,

structured phenotype-based treatment algorithms,

formal recognition of inability to belch syndrome, and

stricter CHS criteria.

The single most important Rome V advance in gastroduodenal disease is this: symptom-pattern phenotyping now drives both diagnosis and treatment more explicitly than ever before.